Seagen To Surge Ahead As ADCs Become Frontline Cancer Therapies

Padcev Plus Keytruda To Become Bladder Cancer Blockbuster

Putting its CEO crisis and takeover rumors behind it, Seagen has big plans to expand its leading position in antibody-drug conjugates in 2023.

Seagen
Adcetris and Padcev will be the company's two main growth drivers this year. • Source: Shutterstock

Seagen looks set to sustain double-digit growth in 2023 as its antibody-drug conjugates (ADCs) expand into first-line uses, led by the lymphoma treatment Adcetris and urothelial cancer therapy, Padcev.

ADCs, which harness antibodies to deliver targeted cytotoxic payloads to tumors, have become one of the fastest-growing classes in oncology,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.